SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES

1 - 52 . (canceled)

53 . A method of treating a patient in need thereof comprising administering an effective amount of a composition comprising a binding polypeptide comprising at least one modified glycan, wherein the glycan comprises at least one moiety of Formula (IV):

wherein:

A) Q is NH or O;

B) CON is a connector moiety;

C) X is a targeting moiety;

D) Gal is a component derived from galactose; and

E) Sia is a component derived from sialic acid, wherein Sia is present or absent, and

wherein the targeting moiety binds to a cell and a pharmaceutically acceptable carrier or excipient.

54 . The method of claim 53 , wherein one or more of the following conditions is met:

a) the cell is a mammalian cell;

b) the binding polypeptide is internalized by the cell;

c) the targeting moiety binds to a mannose 6 phosphate receptor on the cell;

d) the targeting moiety binds to a sialic acid-binding immunoglobulin-type lectin (Siglec) on the cell;

e) the targeting moiety binds to a C-type lectin receptor, a galectin, or a L-type lectin receptor;

f) Q is O;

g) the glycan comprises at least one moiety of the following structural formula:

and

h) the targeting moiety is a glycopeptide capable of binding an asialoglycoprotein receptor (ASGPR) on a cell.

55 . The method of claim 54 , wherein one or more of the following conditions is met:

a) the mammalian cell is selected from an immune cell, a liver cell, a tumor cell, a vascular cell, an epithelial cell, or a mesenchymal cell;

b) the amount of the binding polypeptide internalized by the cell is greater than the amount of a reference binding polypeptide lacking a targeting moiety internalized by the cell;

c) the targeting moiety comprises a mannose 6 phosphate moiety;

d) the Siglec is sialoadhesin (Siglec-1), CD22 (Siglec-2), CD33 (Siglec-3), myelin-associated glycoprotein (MAG (Siglec-4)), Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, Siglec-10, Siglec-11, Siglec-12, Siglec-14, or Siglec-15;

e) the targeting moiety comprises an α2,3-, α2,6-, or α2,8-linked sialic acid residue;

f) the targeting moiety binds to DEC-205 (CD205; lymphocyte antigen 75), macrophage mannose receptor (MMR; CD206), Dectin-1, Dectin-2, macrophage-inducible C-type lectin (Mincle), dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN, CD209), DC NK lectin group receptor-1 (DNGR-1), Langerin (CD207), a lectican, an asialoglycoprotein receptor (ASGPR), C-lectin receptor dendritic cell immunoreceptor (CLEC4A; CLECSF6; DCIR), macrophage galactose-type lectin (MGL), a DC receptor, a collectin, a selectin, an NK-cell receptor, a multi-C-type lectin domain (CTLD) endocytic receptor, a Reg group (type VII) lectin, chondrolectin, tetranectin, polycystin, attractin (ATRN), eosinophil major basic protein (EMBP), DiGeorge Syndrome Critical Region Gene 2 (DGCR2), Thrombomodulin, Bimlec, a group XVI lectin (SEEC), or a group XVII lectin (CBCP/Frem1/QBRICK); and

g) the targeting moiety is a trivalent GalNAc glycan moiety.

56 . The method of claim 54 , wherein the mammalian cell is selected from a B cell, a T cell, a dendritic cell, a natural killer (NK) cell, a macrophage, a neutrophil, a hepatocyte, a liver sinusoidal endothelial cell, or a hepatoma cell.

57 . The method of claim 55 , wherein the targeting moiety comprises an α2,3-siallylactose moiety or an α2,6-siallylactose moiety.

58 . The method of claim 55 , wherein the targeting moiety is a tri-galactosylated glycopeptide or lactose 3 -Cys 3 Gly 4 .

59 . The method of claim 58 , wherein Sia is present and the lactose 3 -Cys 3 Gly 4 moiety is represented by Formula V:

60 . The method of claim 59 , wherein the glycan comprises at least one moiety selected from the following structural formulae:

61 . The method of claim 54 , wherein the targeting moiety is a trivalent GalNAc glycan moiety.

62 . The method of claim 61 , wherein one or more of the following conditions are met:

a) Sia is present and the trivalent GalNAc glycan moiety is represented by Formula VIII:

wherein q is an integer between 1 and 29 inclusive;

b) wherein the glycan comprises at least one moiety having the following structural formula:

wherein q is an integer between 1 and 29 inclusive;

c) wherein the glycan comprises at least one moiety having the following structural formula:

wherein q is an integer between 1 and 29 inclusive;

d) the trivalent GalNAc glycan moiety is represented by Formula VII, Formula XIII, or Formula XIV:

and

e) the glycan comprises at least one moiety selected from the following structural formulae:

63 . The method of claim 53 , wherein one or more of the following conditions is met:

a) the binding polypeptide comprises an Fc domain;

b) the Fc domain is human;

c) the binding polypeptide comprises a CH1 domain

d) the connector moiety comprises a pH-sensitive linker, disulfide linker, enzyme-sensitive linker or other cleavable linker moiety;

e) the connector moiety comprises a linker moiety selected from the group consisting of linker moieties depicted in Table 2 and 14; and

f) the binding polypeptide is an antibody or immunoadhesin.

64 . The method of claim 63 , wherein one or more of the following conditions is met:

a) the modified glycan is N-linked to the binding polypeptide via an asparagine residue at amino acid position 297 of the Fc domain, according to EU numbering;

b) the modified glycan is N-linked to the binding polypeptide via an asparagine residue at amino acid position 298 of the Fc domain, according to EU numbering; and

c) the modified glycan is N-linked to the binding polypeptide via an asparagine residue at amino acid position 114 of the CH1 domain, according to Kabat numbering.

65 . The method of claim 53 , wherein the binding polypeptide comprising the glycan comprises one or two terminal sialic acid residues.

66 . The method of claim 65 , where the terminal sialic acid residues are introduced by treatment of the binding polypeptide with a sialyltransferase or combination of sialyltransferase and galactosyltransferase.

67 . The method of claim 53 , wherein the ratio of targeting moiety to binding polypeptide is equal to or more than about 4 or wherein the ratio of targeting moiety to binding polypeptide is at least about 2.

68 . The method of claim 53 , wherein one or more of the following conditions is met:

a) the binding protein comprises an N-glycan glycoform selected from the group consisting of: a G0 glycoform, a G1 glycoform, and a G2 glycoform;

b) the N-glycan glycoform is selected from the group consisting of: a G1S1 glycoform, a G2S1 glycoform, and a G2S2 glycoform; and

c) the N-glycan glycoform is selected from the group consisting of: a G1F glycoform, a G2F glycoform, a G1S1F glycoform, a G2S1F glycoform, and a G2S2F glycoform.

69 . The method of claim 53 , wherein one or more of the following conditions is met:

a) the method is administered for treating cancer, inflammation, or autoimmune disease;

b) the patient is a human;

c) the patient has a Her2+ tumor; and

d) the binding polypeptide is specific for CD52, αβTCR, or TEM1.

70 . A method of treating a patient in need thereof comprising administering an effective amount of a composition comprising a binding polypeptide comprising at least one modified glycan comprising at least one moiety of Formula (IV):

wherein:

A) Q is NH or O;

B) CON is a connector moiety;

C) X is a moiety comprising PEG;

D) Gal is a component derived from galactose; and

E) Sia is a component derived from sialic acid,

wherein Sia is present or absent

and a pharmaceutically acceptable carrier or excipient.

71 . The method of claim 70 , wherein one or more of the following conditions are met:

a) the glycan comprises at least one moiety represented by Formula IX or Formula XI:

wherein p has a value of 1 to 32; or

wherein p has a value of 1 to 32;

b) the glycan comprises at least one moiety selected from the following structural formulae:

wherein p has a value of 1 to 32,

wherein p has a value of 1 to 32

wherein p has a value of 1 to 32; or

wherein p has a value of 1 to 32;

c) the targeting moiety comprises PEG and is represented by Formula X or Formula XII:

and

d) the glycan comprises at least one moiety selected from the following structural formulae:

72 . The method of claim 70 , wherein one or more of the following conditions is met:

a) the PEG comprises mono-PEG, bi-PEG, or tri-PEG;

b) the PEG comprises 3 to 3.5 PEG; and

c) the binding polypeptide is an antibody or immunoadhesin.